| 李雯妮,张春炳,王俊琳,葛丽娜,山洁慧,李 敏,刘建平.通脉养心丸对冠状动脉粥样硬化性心脏病伴慢性病贫血患者铁调素水平的影响[J].,2017,17(24):4653-4656 |
| 通脉养心丸对冠状动脉粥样硬化性心脏病伴慢性病贫血患者铁调素水平的影响 |
| Effect of Tongmai Yangxin Pill on the Serum Hepcidin Level of Patients with Coronary Atherosclerotic Heart Disease and Anemia of Chronic Disease |
| 投稿时间：2017-02-21 修订日期：2017-03-07 |
| DOI：10.13241/j.cnki.pmb.2017.24.012 |
| 中文关键词: 慢性病贫血 铁调素 通脉养心丸 冠状动脉粥样硬化性心脏病 |
| 英文关键词: Anemia of Chronic Disease Hepcidin Tongmai Yangxin Pill Coronary Atherosclerotic Heart Disease |
| 基金项目:上海交通大学医学院附属仁济医院南院横向课题TJZX[2015]；上海市市级医院新兴前沿技术联合攻关项目 |
|
| 摘要点击次数: 251 |
| 全文下载次数: 137 |
| 中文摘要: |
| 摘要 目的：探讨通脉养心丸对冠状动脉粥样硬化性心脏病(CAD)伴慢性病贫血(ACD)患者铁调素水平的影响。方法：于2015年4月-2016年6月在上海交通大学医学院附属仁济医院(南院)接受治疗的患者中选取70例年龄≥40岁的冠状动脉粥样硬化性心脏病伴慢性病贫血患者并随机分成两组，每组各35人，分别服用通脉养心丸(II组)或未服用通脉养心丸(III组)。同时选取冠心病患者不伴有慢性病贫血40人为对照组(I组)，该组患者服用通脉养心丸。观察比较三组服药8周前后的血铁调素及血红蛋白、铁蛋白水平的变化。结果：服药前，II、III组的血Hepc水平均明显高于I组(P<0.05)。8周治疗后，II组患者血Hepc表达明显下降，Hb水平较治疗前显著升高(P<0.05)，其余两组血Hepc表达与治疗前相比差异无统计学意义(P>0.05)；II组、III组血Hepc水平显著高于I组(P<0.05)，III组的血Hepc水平显著高于II组；III组患者的Hb水平明显低于I组、II组(P<0.05)。结论：通脉养心丸能降低冠状动脉粥样硬化性心脏病伴慢性病贫血患者的铁调素水平，提高该类患者的血红蛋白值，对冠状动脉粥样硬化性心脏病伴慢性病贫血患者，尤其是轻度贫血患者有一定的治疗价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Tongmai Yangxin Pill on the serum hepcidin level of patients with Coronary Atherosclerotic Heart Disease and Anemia of Chronic Disease. Methods: Seventy patients with Coronary Atherosclerotic Heart Disease and Anemia of Chronic Disease whose age were above 40 years old were enrolled as the research group and divided into the medication group (group II) (n=35) and the nonmedication group (group III)(n=35), while 40 CAD patients were enrolled as the normal control group (group I). Before and after medication, the Hepc, Hb, etc levels were compared between two groups. Results: Before medication, the levels of Hepc in the two research subgroup were significantly higher than that of the control group(P<0.05). At 8 weeks after treatment, the Hepc level of group II was significantly declined, and the level of Hb was increased than those before treatment(P <0.05); the Hepc levels of group I and group III showed no significant difference(P>0.05), the Hepc levels of group II and group III were obviously higher than that of the control group(P <0.05), the Hepc levels of group III was obviously higher than that of the group II(P<0.05), the Hb level of group III was obviously lower than those of group I and group II(P<0.05). Conclusion: Tongmai Yangxin Pill could reduce the level of Hepc and enhance the Hb levels of patients with Coronary Atherosclerotic Heart Disease and Anemia of Chronic Disease. It was useful to the patients with Coronary Atherosclerotic Heart Disease and Anemia of Chronic Disease, especially patients with mild anemia. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
